News & Updates

Use of fezolinetant demonstrates efficacy and good tolerability in the treatment of moderate-to-severe vasomotor symptoms associated with menopause in women who are deemed unsuitable for hormone therapy, reports a study.

Results of the phase III ASSURE study support seladelpar – a novel first-in-class delpar (selective peroxisome proliferator-activated receptor delta agonist) – for the treatment of primary biliary cholangitis (PBC).

Metformin prescribed within a week of SARS-CoV-2 infection was associated with a 53-percent reduction in long COVID or death over 6 months in patients without diabetes or prediabetes, as shown in a simulation study presented at IDWeek 2024.

The overall utilization rates of SGLT2 inhibitors have increased among patients with type 2 diabetes (T2D) following the release of the 2022 American Diabetes Association (ADA) guidelines.

A study suggests that in choosing CDK4/6 inhibitors (palbociclib and abemaciclib) for patients with hormone receptor-positive, HER2-negative metastatic/recurrent breast cancer, considerations must be made based on the tolerability and manageability of adverse events (AEs).